Vita Life Sciences Limited (VLS) AI Stock Analysis

• Market Cap: AU$146.93M
• Dividend Yield: 4.33%
• Average Volume (3M): 14.76K
• Price to Earnings (P/E): 14.3
• Beta (1Y): -0.14
• Revenue Growth: 8.46%
• EPS Growth: -1.95%
• Country: AU
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.10
• Shares Outstanding: 54,620,354
• 10 Day Avg. Volume: 12,408
• 30 Day Avg. Volume: 14,758
• PEG Ratio: 0.74
• Price to Book (P/B): 2.57
• Price to Sales (P/S): 1.55
• P/FCF Ratio: 9.11
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 82 Outperform
• Price Target: AU$3.00 ▲(19.05% Upside)
• Action: Reiterated Date: 02/20/26
• Date: Action: Reiterated 02/20/26

The score is driven primarily by strong financial performance (consistent growth, solid margins, and low leverage). Valuation is supportive with a reasonable P/E and a ~4.15% dividend yield. Technicals are positive but moderate, with an established uptrend and largely neutral momentum readings.

Positive Factors

Revenue Growth

Sustained revenue expansion over multiple years shows durable end-market demand and successful distribution execution. A doubling of sales since 2020 indicates scalable product-market fit and provides a base for continued investment in channels and R&D, supporting medium-term growth prospects.

High Gross Margins

Consistently high gross margins indicate persistent product-level pricing power and favorable cost structure in core supplements. This margin profile supports durable operating profit generation, enabling reinvestment and dividend capacity even if SG&A rises moderately as the company scales.

Conservative Balance Sheet

Low leverage and a meaningful equity build provide financial flexibility for organic growth, M&A, or cyclical shocks. Strong recent ROE shows effective capital deployment historically, reducing solvency risk and supporting sustainable shareholder distributions and strategic investments over the coming months.

Negative Factors

Margin Compression

A multi-year decline in net margin suggests rising cost pressures or less favourable mix as the business scales. If structural, persistent margin erosion would reduce free cash flow and limit reinvestment or payout capacity unless offset by pricing, efficiency gains, or higher-margin product development.

Cash Flow Volatility

Inconsistent cash conversion points to working-capital swings or timing differences that make free cash flow less predictable. This variability can complicate capital allocation, dividend planning and stress testing for expansion, increasing operational risk despite healthy headline profitability.

Declining Returns on Capital

A downward trend in returns suggests incremental investments are yielding lower returns than earlier cycles. Over time this can constrain value creation, requiring either higher growth, improved margins, or more disciplined capital allocation to sustain shareholder returns at prior levels.

Vita Life Sciences Limited Business Overview & Revenue Model

Company Description

Vita Life Sciences Limited (VLS) is a health and wellness company that specializes in the development and distribution of nutritional supplements and dietary products. The company operates primarily in the consumer health sector, focusing on providing high-quality vitamins, minerals, and herbal supplements. VLS aims to enhance the well-being of its customers through its innovative product offerings, which cater to various health needs and promote a balanced lifestyle.

How the Company Makes Money

Vita Life Sciences Limited generates revenue through the sale of its range of nutritional supplements and health products, which are marketed to both consumers and healthcare professionals. The company employs a multi-channel distribution strategy, including direct sales, partnerships with retailers, and e-commerce platforms, allowing it to reach a broad audience. Key revenue streams include product sales, online orders, and collaborations with health practitioners who recommend VLS products. Additionally, VLS may benefit from strategic partnerships with other health and wellness brands, enhancing its market presence and sales potential.

Vita Life Sciences Limited Financial Statement Overview

Summary

Strong fundamentals: steady revenue growth through 2025, durable profitability (gross margin ~57%–63%, net margin ~11% recently), and a conservatively financed balance sheet with very low leverage and solid ROE. Offsets include modest margin compression versus earlier years and some volatility in cash generation.

Income Statement

Revenue has grown steadily from 2020 to 2025 (from ~A$46.5m to ~A$93.3m), with strong recent momentum in 2025. Profitability is solid, with gross margin consistently around ~57%–63% and a healthy net margin around ~11% in 2024–2025. The main offset is margin compression versus earlier years (net margin down from ~14.5% in 2021 to ~11% recently, and EBIT/EBITDA margins have trended modestly lower), suggesting cost pressure as the business scales.

Balance Sheet

The balance sheet is conservatively positioned with very low leverage; debt remains small relative to equity across the period, even after the increase in 2025. Equity has compounded meaningfully (from ~A$24.7m in 2020 to ~A$56.3m in 2025), supporting asset growth. Returns on shareholder capital are strong (mid-to-high teens recently), though down from peak levels in 2020–2021, implying incremental capital is generating slightly lower returns than before.

Cash Flow

Free cash flow is high quality relative to profits, running close to net income across all years, which supports earnings credibility. 2025 showed a major step-up in operating and free cash flow with strong growth. The key weakness is volatility in cash generation year-to-year (notably weaker cash flow conversion in 2024 versus earnings, then a sharp rebound in 2025), which can indicate working-capital swings and less predictable cash timing.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	93.27M	79.50M	74.16M	66.89M	57.10M
Gross Profit	56.03M	47.24M	42.60M	39.74M	34.81M
EBITDA	15.66M	13.46M	13.10M	11.37M	11.71M
Net Income	10.44M	8.78M	9.08M	7.08M	8.29M
Balance Sheet
Total Assets	82.36M	71.89M	59.81M	51.80M	45.27M
Cash, Cash Equivalents and Short-Term Investments	35.56M	28.60M	24.63M	15.69M	15.89M
Total Debt	4.30M	517.00K	387.00K	601.00K	373.00K
Total Liabilities	26.20M	19.61M	16.48M	15.30M	14.85M
Stockholders Equity	56.25M	52.35M	43.40M	36.57M	30.75M
Cash Flow
Free Cash Flow	15.86M	5.96M	12.32M	7.54M	5.73M
Operating Cash Flow	16.43M	6.16M	12.98M	7.68M	5.89M
Investing Cash Flow	-570.00K	-198.00K	-660.00K	-139.00K	-155.00K
Financing Cash Flow	-9.09M	-2.99M	-2.88M	-3.10M	-4.39M

Vita Life Sciences Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.52
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:VLS, the sentiment is Positive. The current price of 2.52 is below the 20-day moving average (MA) of 2.60, below the 50-day MA of 2.61, and above the 200-day MA of 2.35, indicating a bullish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 56.23 is Neutral, neither overbought nor oversold. The STOCH value of 72.10 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:VLS.

Vita Life Sciences Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VLS	82 Outperform	AU$146.93M	14.33	18.35%	4.33%	8.46%	-1.95%
VIT	57 Neutral	AU$27.84M	35.83	7.64%	3.28%	0.13%	-12.90%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MVP	46 Neutral	AU$49.57M	-112.82	0.19%	―	17.82%	―
IDT	45 Neutral	AU$20.56M	-3.47	-35.58%	―	45.30%	-24.18%

Vita Life Sciences Limited Corporate Events

Vita Life Sciences Cancels 18,584 Shares Under On‑Market Buy-Back

Vita Life Sciences Limited has cancelled 18,584 ordinary fully paid shares on 19 December 2025 as part of an on-market share buy-back program, according to its latest capital notification. The reduction in issued capital forms part of the company’s ongoing capital management strategy and marginally increases the ownership percentage of remaining shareholders, signalling continued efforts to optimise its balance sheet and potentially enhance shareholder value.

The most recent analyst rating on (AU:VLS) stock is a Buy with a A$3.00 price target. To see the full list of analyst forecasts on Vita Life Sciences Limited stock, see the AU:VLS Stock Forecast page.

Vita Life Sciences Projects Strong FY2025 Growth Amid Market Expansion

Vita Life Sciences has issued its FY2025 guidance, projecting significant sales growth to $91m-$92m, up from $79.5m in FY2024, and a pre-tax profit increase to $13.2m-$13.7m. The growth is driven by robust performance in Malaysia and Singapore, with anticipated 30% revenue growth, and steady contributions from the Australian market. However, export sales to China are expected to fall short of initial expectations due to trade partner transitions. The company is committed to investing in brand development and market positioning to support long-term growth, focusing on core markets and exploring new opportunities in Vietnam and China.

The most recent analyst rating on (AU:VLS) stock is a Buy with a A$2.50 price target. To see the full list of analyst forecasts on Vita Life Sciences Limited stock, see the AU:VLS Stock Forecast page.

Vita Life Sciences Updates on Share Buy-Back Program

Vita Life Sciences Limited has announced an update on its ongoing share buy-back program. The company reported that it bought back 18,584 ordinary fully paid securities on the previous day, adding to a total of 541,740 securities repurchased prior to that day. This buy-back initiative is part of Vita Life Sciences’ strategy to manage its capital structure and potentially enhance shareholder value.

The most recent analyst rating on (AU:VLS) stock is a Buy with a A$2.50 price target. To see the full list of analyst forecasts on Vita Life Sciences Limited stock, see the AU:VLS Stock Forecast page.

Vita Life Sciences Announces Cessation of Securities Through Buy-Back

Vita Life Sciences Limited announced the cessation of 3,062 ordinary fully paid securities due to an on-market buy-back, effective December 10, 2025. This move could potentially impact the company’s capital structure and market perception, as buy-backs are often seen as a signal of management’s confidence in the company’s future prospects.

The most recent analyst rating on (AU:VLS) stock is a Buy with a A$2.50 price target. To see the full list of analyst forecasts on Vita Life Sciences Limited stock, see the AU:VLS Stock Forecast page.

Vita Life Sciences Announces Cessation of Securities

Vita Life Sciences Limited announced the cessation of 104,392 ordinary fully paid securities as part of an on-market buy-back, effective November 24, 2025. This move is likely to impact the company’s capital structure and could influence its market positioning by potentially increasing shareholder value through a reduction in outstanding shares.

The most recent analyst rating on (AU:VLS) stock is a Buy with a A$2.50 price target. To see the full list of analyst forecasts on Vita Life Sciences Limited stock, see the AU:VLS Stock Forecast page.